| An antibody-drug conjugate is being developed by Immunomedics for the treatment of solid tumours |
| Received its first approval on 22 April 2020 in the USA |
| Approved for use in adult patients with mTNBC who have received at least two prior therapies for metastatic disease |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.